Stryker Corporation vs Millicom International Cellular S.A. Common Stock — how do they compare? Stryker Corporation trades at $285 (market cap $108.38B), while Millicom International Cellular S.A. Common Stock trades at $80.5 (market cap $13.34B). The key difference: Stryker Corporation is far larger — about 8.1× Millicom International Cellular S.A. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 22 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| SYK | TIGO | |
|---|---|---|
Market Cap | $108.38B | $13.34B |
Volume | 2,068,363 | 1,586,684 |
Sector | Health | Media |
52-Week High | $388.35 | $104.31 |
52-Week Low | $269.75 | $45.81 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $119.84B | $24.38B |
Dividend Yield | 1.25% | 3.77% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →